Sr. Kempf et al., ANTICARCINOGENIC EFFECT OF TETRACHLORODECAOXIDE AFTER TOTAL-BODY GAMMA-IRRADIATION IN RATS, Radiation research, 139(2), 1994, pp. 226-231
Tetrachlorodecaoxygen (TCDO) therapy of acute radiation syndrome was t
ested for a possible influence on the development of X-ray-induced mal
ignancies. BD IX rats were exposed to total-body irradiation (TBI, gam
ma rays, 9 or 11 Gy) and received daily intravenous injections of eith
er TCDO or physiological saline solution from days 4 through 11 after
TBI. The short-term TCDO therapy reduced the acute death rate markedly
, but survival rates after 4 months were similar with and without TCDO
. The first malignancy after TBI occurred on day 103, and over the lif
etime of the animals the tumor incidence in the group given TBI(11 Gy)
without TCDO treatment was 73% vs 20% in animals with short-term TCDO
therapy after TBI. In particular, there was a highly significant prev
ention of radiation-induced leukemia [P (one-sided)< 0.001] by TCDO, a
nd a significantly reduced incidence of malignant epithelial tumors [P
(one-sided) < 0.05]. The development of sarcomas was not affected by
TCDO. Long-term survival was not enhanced by TCDO due to the occurrenc
e of bronchopneumonial infections about 1 year after TBI. In conclusio
n, TCDO is not only a potent therapeutic agent in acute radiation synd
rome, but it also significantly reduced the carcinogenic risk in rats
after exposure to ionizing radiation.